Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity

被引:5
|
作者
Flury, Philipp [1 ,2 ]
Breidenbach, Julian [3 ]
Krueger, Nadine [4 ]
Voget, Rabea [3 ]
Schaekel, Laura [3 ]
Si, Yaoyao [3 ]
Krasniqi, Vesa [3 ]
Calistri, Sara [1 ,2 ]
Olfert, Matthias [5 ]
Sylvester, Katharina [3 ]
Rocha, Cheila [4 ]
Ditzinger, Raphael [1 ,2 ]
Rasch, Alexander [1 ,2 ]
Poehlmann, Stefan [4 ,5 ]
Kronenberger, Thales [1 ,2 ,6 ,7 ]
Poso, Antti [1 ,2 ,6 ]
Rox, Katharina [8 ,9 ]
Laufer, Stefan A. [1 ,2 ]
Mueller, Christa E. [2 ,3 ]
Guetschow, Michael [3 ]
Pillaiyar, Thanigaimalai [1 ,2 ]
机构
[1] Eberhard Karls Univ Tubingen, Inst Pharm Pharmaceut Med Chem, D-72076 Tubingen, Germany
[2] Eberhard Karls Univ Tubingen, Tubingen Ctr Acad Drug Discovery, D-72076 Tubingen, Germany
[3] Univ Bonn, Pharmaceut Inst, PharmaCtr Bonn, Pharmaceut & Med Chem, D-53121 Bonn, Germany
[4] Leibniz Inst Primate Res, German Primate Ctr, Infect Biol Unit, D-37077 Gottingen, Germany
[5] Univ Goettingen, Fac Biol & Psychol, D-37073 Gottingen, Germany
[6] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70211, Finland
[7] Excellence Cluster Controlling Microbes Fight Inf, D-72076 Tubingen, Germany
[8] Helmholtz Ctr Infect Res HZI, Dept Chem Biol, D-38124 Braunschweig, Germany
[9] German Ctr Infect Res DZIF, Partner Site Hannover Braunschweig, D-38124 Braunschweig, Germany
关键词
COVID-19; cathepsininhibitors; main protease; peptidomimetics; SARS-CoV-2; viral entry; MAIN PROTEASE; CYSTEINE; ENTRY; REACTIVITY; DISCOVERY;
D O I
10.1021/acsptsci.3c00313
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cathepsins (Cats) are proteases that mediate the successful entry of SARS-CoV-2 into host cells. We designed and synthesized a tailored series of 21 peptidomimetics and evaluated their inhibitory activity against human cathepsins L, B, and S. Structural diversity was realized by combinations of different C-terminal warhead functions and N-terminal capping groups, while a central Leu-Phe fragment was maintained. Several compounds were identified as promising cathepsin L and S inhibitors with K-i values in the low nanomolar to subnanomolar range, for example, the peptide aldehydes 9a and 9b (9a, 2.67 nM, CatL; 0.455 nM, CatS; 9b, 1.76 nM, CatL; 0.512 nM, CatS). The compounds' inhibitory activity against the main protease of SARS-CoV-2 (M-pro) was additionally investigated. Based on the results at CatL, CatS, and M-pro, selected inhibitors were subjected to investigations of their antiviral activity in cell-based assays. In particular, the peptide nitrile 11e exhibited promising antiviral activity with an EC50 value of 38.4 nM in Calu-3 cells without showing cytotoxicity. High metabolic stability and favorable pharmacokinetic properties make 11e suitable for further preclinical development.
引用
收藏
页码:493 / 514
页数:22
相关论文
共 50 条
  • [31] Design, Synthesis, Evaluation, and Molecular Dynamics Simulation of SARS-CoV-2 Mpro Inhibitors
    Yang, Qinghua
    Zong, Keli
    Zhao, Xu
    Zhang, Fenghua
    Li, Fei
    Li, Xingzhou
    ACS MEDICINAL CHEMISTRY LETTERS, 2025, : 668 - 674
  • [32] Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19
    Steuten, Kas
    Kim, Heeyoung
    Widen, John C.
    Babin, Brett M.
    Onguka, Ouma
    Lovell, Scott
    Bolgi, Oguz
    Cerikan, Berati
    Neufeldt, Christopher J.
    Cortese, Mirko
    Muir, Ryan K.
    Bennett, John M.
    Geiss-Friedlander, Ruth
    Peters, Christoph
    Bartenschlager, Ralf
    Bogyo, Matthew
    ACS INFECTIOUS DISEASES, 2021, 7 (06): : 1457 - 1468
  • [33] Synthesis, characterization, proteolytic activity inhibition, ADMET prediction, and molecular docking studies of novel indole derivatives as potential SARS-CoV-2 protease inhibitors
    Chihab, Abdelali
    El Brahmi, Nabil
    El Abbouchi, Abdelmoula
    El Alaoui, Abdelaziz
    Bousmina, Mostapha
    El Fahime, Elmostafa
    El Kazzouli, Said
    JOURNAL OF MOLECULAR STRUCTURE, 2025, 1323
  • [34] Design, Synthesis, and Biological Evaluation of Peptidomimetic Tetrahydropyrrole Spirodihydroindolones as SARS-CoV-2 3CL Protease Inhibitors
    Hu, Liuyan
    Zhao, Zhi
    Zhang, Shujing
    Yang, Lei
    Cui, Wenjie
    Hu, Tianwen
    Suo, Jin
    Sun, Haiguo
    Zhang, Qiumeng
    Zhang, Leike
    Zhu, Weiliang
    Xu, Zhijian
    Zhang, Yumin
    Jiang, Xiangrui
    Zhang, Yan
    Shen, Jingshan
    ACS MEDICINAL CHEMISTRY LETTERS, 2025,
  • [35] Design of novel and highly selective SARS-CoV-2 main protease inhibitors
    Poli, Adi N. R.
    Tietjen, Ian
    Nandwana, Nitesh K.
    Cassel, Joel
    Messick, Troy E.
    Register, Emery T.
    Keeney, Frederick
    Rajaiah, Rajesh
    Verma, Atul K.
    Pandey, Kabita
    Acharya, Arpan
    Byrareddy, Siddappa N.
    Montaner, Luis J.
    Salvino, Joseph M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (10)
  • [36] SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors
    Citarella, Andrea
    Scala, Angela
    Piperno, Anna
    Micale, Nicola
    BIOMOLECULES, 2021, 11 (04)
  • [37] Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 inhibitors
    Valipour, Mehdi
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 240
  • [38] SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies
    Fischer, Conrad
    Feys, Jenson R.
    FUTURE PHARMACOLOGY, 2023, 3 (01): : 80 - 107
  • [39] The natural tannins oligomeric proanthocyanidins and punicalagin are potent inhibitors of infection by SARS-CoV-2
    Chen, Hsiao-Fan
    Wang, Wei-Jan
    Chen, Chung-Yu
    Chang, Wei-Chao
    Hsueh, Po-Ren
    Peng, Shin-Lei
    Wu, Chen-Shiou
    Chen, Yeh
    Huang, Hsin-Yu
    Shen, Wan-Jou
    Wang, Shao-Chun
    Hung, Mien-Chie
    ELIFE, 2023, 12
  • [40] Conventional Understanding of SARS-CoV-2 Mpro and Common Strategies for Developing Its Inhibitors
    Zhou, Kun
    Chen, Daquan
    CHEMBIOCHEM, 2023,